JP2002536399A - 筋肉内および皮内投与のためのポリヌクレオチド組成物 - Google Patents
筋肉内および皮内投与のためのポリヌクレオチド組成物Info
- Publication number
- JP2002536399A JP2002536399A JP2000598139A JP2000598139A JP2002536399A JP 2002536399 A JP2002536399 A JP 2002536399A JP 2000598139 A JP2000598139 A JP 2000598139A JP 2000598139 A JP2000598139 A JP 2000598139A JP 2002536399 A JP2002536399 A JP 2002536399A
- Authority
- JP
- Japan
- Prior art keywords
- block copolymer
- composition
- polynucleotide
- copolymer
- poly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F290/00—Macromolecular compounds obtained by polymerising monomers on to polymers modified by introduction of aliphatic unsaturated end or side groups
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F297/00—Macromolecular compounds obtained by successively polymerising different monomer systems using a catalyst of the ionic or coordination type without deactivating the intermediate polymer
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L51/00—Compositions of graft polymers in which the grafted component is obtained by reactions only involving carbon-to-carbon unsaturated bonds; Compositions of derivatives of such polymers
- C08L51/003—Compositions of graft polymers in which the grafted component is obtained by reactions only involving carbon-to-carbon unsaturated bonds; Compositions of derivatives of such polymers grafted on to macromolecular compounds obtained by reactions only involving unsaturated carbon-to-carbon bonds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L53/00—Compositions of block copolymers containing at least one sequence of a polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds; Compositions of derivatives of such polymers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
- C08L71/02—Polyalkylene oxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/227,364 | 1999-01-08 | ||
US09/227,364 US6359054B1 (en) | 1994-11-18 | 1999-01-08 | Polynucleotide compositions for intramuscular administration |
PCT/US2000/000309 WO2000047186A1 (en) | 1999-01-08 | 2000-01-06 | Polynucleotide compositions for intramuscular and intradermal administration |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2002536399A true JP2002536399A (ja) | 2002-10-29 |
Family
ID=22852805
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000598139A Withdrawn JP2002536399A (ja) | 1999-01-08 | 2000-01-06 | 筋肉内および皮内投与のためのポリヌクレオチド組成物 |
Country Status (6)
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020123476A1 (en) * | 1991-03-19 | 2002-09-05 | Emanuele R. Martin | Therapeutic delivery compositions and methods of use thereof |
US6933286B2 (en) * | 1991-03-19 | 2005-08-23 | R. Martin Emanuele | Therapeutic delivery compositions and methods of use thereof |
DE19903693A1 (de) * | 1998-04-24 | 1999-10-28 | Centeon Pharma Gmbh | Protease zur Aktivierung des Gerinnungsfaktors VII |
US6244331B1 (en) * | 1999-10-22 | 2001-06-12 | Intel Corporation | Heatsink with integrated blower for improved heat transfer |
AU780270B2 (en) * | 2000-02-23 | 2005-03-10 | Association Francaise Contre Les Myopathies | Treatment of immune diseases |
EP1309904A4 (en) * | 2000-03-03 | 2006-03-29 | Valentis Inc | IMPROVED POLOXAMER AND POLYOAMINE COMPOUNDS FOR NUCLEINE SUCTION INTRODUCTION |
WO2001080897A2 (en) * | 2000-04-21 | 2001-11-01 | Vical Incorporated | Compositions and methods for in vivo delivery of polynucleotide-based therapeutics |
US7256180B2 (en) * | 2000-04-28 | 2007-08-14 | Supratek Pharma Inc. | Compositions and methods for inducing activation of dendritic cells |
CA2354756C (en) * | 2000-08-10 | 2006-05-30 | Jds Uniphase Inc. | Optical device package |
JP2002170377A (ja) * | 2000-09-22 | 2002-06-14 | Mitsubishi Electric Corp | 薄膜磁性体記憶装置 |
CA2426582A1 (en) * | 2000-10-20 | 2002-08-08 | Valentis, Inc. | Gene delivery formulations and methods for treatment of ischemic conditions |
EP1421170A2 (en) * | 2001-07-31 | 2004-05-26 | CytRx Corporation | Therapeutic delivery compositions and methods of use thereof |
US20030191081A1 (en) * | 2001-12-28 | 2003-10-09 | Pierre Lemieux | Pharmaceutical compositions and methods of use thereof comprising polyanionic polymers and amphiphilic block copolymers to improve gene expression |
FR2835749B1 (fr) | 2002-02-08 | 2006-04-14 | Inst Nat Sante Rech Med | Composition pharmaceutique ameliorant le transfert de gene in vivo |
WO2004060059A2 (en) * | 2002-12-23 | 2004-07-22 | Vical Incorporated | Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes |
AU2003293196A1 (en) * | 2002-12-23 | 2004-07-29 | Vical Incorporated | Method for producing sterile polynucleotide based medicaments |
EP2241330A1 (en) | 2003-02-14 | 2010-10-20 | The Curators Of The University Of Missouri | Contraceptive methods and compositions related to proteasomal interference |
US20040230431A1 (en) * | 2003-05-14 | 2004-11-18 | Gupta Sunil K. | Automatic assessment of phonological processes for speech therapy and language instruction |
US20050014714A1 (en) * | 2003-06-04 | 2005-01-20 | The Johns Hopkins University | Gene delivery to organs |
US7422875B2 (en) | 2004-07-20 | 2008-09-09 | Board Of Regents Of The University Of Nebraska | Compositions and methods for increasing protein production |
US8057821B2 (en) | 2004-11-03 | 2011-11-15 | Egen, Inc. | Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof |
WO2006060723A2 (en) * | 2004-12-03 | 2006-06-08 | Vical Incorporated | Methods for producing block copolymer/amphiphilic particles |
WO2007129395A1 (ja) * | 2006-05-02 | 2007-11-15 | Nippon Soda Co., Ltd. | 液状組成物、液状組成物の製造方法、並びに哺乳動物及び鳥類の外部寄生虫防除剤 |
SE530015C2 (sv) | 2006-06-09 | 2008-02-12 | Becare Orthopedic Thermal Care | Högviskös komposition lämpad för muskelbehandling, vilken komposition innefattar polyoxyetylen-polyoxypropylen-blocksampolymer, samt dyna innefattande kompositionen |
US8784833B2 (en) * | 2006-06-27 | 2014-07-22 | Saint Louis University | Prenatal enzyme replacement therapy for hypophosphatasia |
US7871624B2 (en) * | 2006-06-27 | 2011-01-18 | Saint Louis University | Chimeral polypeptide composition for cross-placenta delivery |
EP2296627A2 (en) * | 2008-05-13 | 2011-03-23 | The University of Washington | Micelles for intracellular delivery of therapeutic agents |
KR101661636B1 (ko) | 2008-05-13 | 2016-09-30 | 유니버시티 오브 워싱톤 | 세포로의 전달을 위한 이블록 공중합체 및 그의 폴리뉴클레오티드 복합체 |
WO2009140423A2 (en) * | 2008-05-13 | 2009-11-19 | University Of Washington | Targeted polymer bioconjugates |
AU2009246329B8 (en) | 2008-05-13 | 2013-12-05 | Phaserx, Inc. | Micellic assemblies |
JP2011523641A (ja) * | 2008-05-13 | 2011-08-18 | ユニヴァーシティ オブ ワシントン | 高分子キャリア |
EP2331069A4 (en) * | 2008-08-22 | 2011-10-26 | Univ Washington | HETEROGENEOUS POLYMER MICELLES FOR INTRACELLULAR DELIVERY |
US9464300B2 (en) * | 2008-11-06 | 2016-10-11 | University Of Washington | Multiblock copolymers |
CA2742955A1 (en) | 2008-11-06 | 2010-05-14 | University Of Washington | Bispecific intracellular delivery vehicles |
AU2013204152B2 (en) * | 2008-11-06 | 2016-04-14 | Phaserx, Inc. | Multiblock copolymers |
US9593169B2 (en) | 2008-12-08 | 2017-03-14 | University Of Washington | Omega-functionalized polymers, junction-functionalized block copolymers, polymer bioconjugates, and radical chain extension polymerization |
WO2011043823A2 (en) * | 2009-10-09 | 2011-04-14 | Georgetown University | Polypeptides that home to atherosclerotic plaque |
US9415113B2 (en) | 2009-11-18 | 2016-08-16 | University Of Washington | Targeting monomers and polymers having targeting blocks |
CA2919828C (en) | 2013-07-30 | 2022-07-19 | Phaserx, Inc. | Block copolymers and their conjugates or complexes with oligonucleotides |
AU2016209295B2 (en) | 2015-01-21 | 2021-08-12 | Genevant Sciences Gmbh | Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells |
US11684584B2 (en) | 2016-12-30 | 2023-06-27 | Genevant Sciences Gmbh | Branched peg molecules and related compositions and methods |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4873083A (en) | 1986-05-15 | 1989-10-10 | Emory University | Fibrinolytic composition |
US5047236A (en) | 1986-05-15 | 1991-09-10 | Emory University | Method of treating stroke |
US5017370A (en) | 1986-05-15 | 1991-05-21 | Emory University | Improved method of performing angioplasty procedures |
US5041288A (en) | 1986-05-15 | 1991-08-20 | Emory University | Method of treating tissue damaged by reperfusion injury |
US4801452A (en) | 1986-05-15 | 1989-01-31 | Hunter Robert L | Fibrinolytic composition |
US5030448A (en) | 1986-05-15 | 1991-07-09 | Emory University | Method of delivering drugs to damaged or diseased tissue |
US4879109A (en) | 1986-05-15 | 1989-11-07 | Emory University | Method for treating burns |
US5693622A (en) | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
NZ244306A (en) | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
DE69229640T2 (de) | 1991-10-04 | 1999-12-16 | Gs Dev Ab Malmoe | Teilchen, methode zur herstellung der teilchen und deren verwendung |
US5470568A (en) | 1992-02-13 | 1995-11-28 | Arch Development Corporation | Methods and compositions of a polymer (poloxamer) for cell repair |
US5573934A (en) * | 1992-04-20 | 1996-11-12 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
US5792751A (en) | 1992-04-13 | 1998-08-11 | Baylor College Of Medicine | Tranformation of cells associated with fluid spaces |
US5605687A (en) | 1992-05-15 | 1997-02-25 | Arch Development Corporation | Methods and compositions of a polymer (poloxamer) for repair of electrical injury |
US5840319A (en) | 1992-10-08 | 1998-11-24 | Alakhov; Valery Yu | Biological agent compositions |
WO1994008564A1 (en) | 1992-10-08 | 1994-04-28 | Valery Yu Alakhov | Composition of antineoplastic agents incorporated in micelles |
US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
US5569468A (en) | 1994-02-17 | 1996-10-29 | Modi; Pankaj | Vaccine delivery system for immunization, using biodegradable polymer microspheres |
DE69535520T2 (de) * | 1994-05-10 | 2008-02-07 | Wyeth | Abgeänderter, verbesserter BRSV Lebend- Impfstoff |
EP1181937A3 (en) * | 1994-08-09 | 2004-02-04 | Cytrx Corporation | Novel vaccine adjuvant and vaccine |
US5552309A (en) | 1994-09-30 | 1996-09-03 | Indiana University Foundation | Use of polyols for improving the introduction of genetic material into cells |
US5656611A (en) | 1994-11-18 | 1997-08-12 | Supratek Pharma Inc. | Polynucleotide compositions |
US6040295A (en) | 1995-01-13 | 2000-03-21 | Genemedicine, Inc. | Formulated nucleic acid compositions and methods of administering the same for gene therapy |
US5766899A (en) * | 1995-02-27 | 1998-06-16 | Board Of Regents , The University Of Texas System | Targeted nucleic acid delivery into liver cells |
US5797870A (en) | 1995-06-07 | 1998-08-25 | Indiana University Foundation | Pericardial delivery of therapeutic and diagnostic agents |
FR2759298B1 (fr) * | 1997-02-10 | 1999-04-09 | Rhone Poulenc Rorer Sa | Formulation de particules agent(s) de transfection cationique(s)/acides nucleiques stabilisees |
-
1999
- 1999-01-08 US US09/227,364 patent/US6359054B1/en not_active Expired - Fee Related
-
2000
- 2000-01-06 WO PCT/US2000/000309 patent/WO2000047186A1/en not_active Application Discontinuation
- 2000-01-06 CA CA 2359886 patent/CA2359886A1/en not_active Abandoned
- 2000-01-06 JP JP2000598139A patent/JP2002536399A/ja not_active Withdrawn
- 2000-01-06 EP EP00908221A patent/EP1140015A4/en not_active Withdrawn
- 2000-01-06 AU AU29608/00A patent/AU2960800A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2359886A1 (en) | 2000-08-17 |
WO2000047186A1 (en) | 2000-08-17 |
EP1140015A4 (en) | 2003-08-06 |
US6359054B1 (en) | 2002-03-19 |
EP1140015A1 (en) | 2001-10-10 |
AU2960800A (en) | 2000-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2002536399A (ja) | 筋肉内および皮内投与のためのポリヌクレオチド組成物 | |
US6353055B1 (en) | Polynucleotide compositions | |
US6440743B1 (en) | Methods of using polynucleotide compositions | |
US5656611A (en) | Polynucleotide compositions | |
US20070219118A1 (en) | Therapeutic methods for nucleic acid delivery vehicles | |
JPH10502918A (ja) | 核酸を含有する組成物、その製造および使用 | |
US6210708B1 (en) | Cationic virosomes as transfer system for genetic material | |
JP2005510572A (ja) | ポリカチオン性水溶性コポリマーおよび生物関門を通してポリアニオン性高分子を輸送する方法 | |
US7256180B2 (en) | Compositions and methods for inducing activation of dendritic cells | |
Hussein et al. | Peptide-based targeted polymeric nanoparticles for siRNA delivery | |
JP2004509838A (ja) | 樹状細胞の活性化誘導のための組成物および方法 | |
JP2003526692A (ja) | ポリヌクレオチド組成物 | |
US20230041342A1 (en) | Alkylated nucleosides, and compositions and methods thereof for nucleic acid delivery | |
Yen | Endosomolytic Biomaterial Vaccines for Cancer Therapy | |
AU1498100A (en) | Polynucleotide compositions | |
Kabiru | DNA condensation and packaging for potential application in gene therapy | |
Goparaju | Evaluation of cationic peptide-plasmid DNA complexes for gene delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A300 | Application deemed to be withdrawn because no request for examination was validly filed |
Free format text: JAPANESE INTERMEDIATE CODE: A300 Effective date: 20070306 |